Some patients with COPD have type 2 inflammation, which may increase exacerbation risk. Dupilumab, a monoclonal antibody, targets type 2 inflammatory cytokines.
New research findings are summarized in a short video.
To see the full article, follow this link: nej.md/3Mkskdy
14 окт 2024